2025年医药行业，一场集体性的 “战略瘦身” 正在上演。加科思以 2 亿元出售非核心项目股权，和黄医药 44.78 亿元剥离中药资产，复星医药 12.56 亿元转让物业资产，百洋医药清退健康管理业务……业内表示，头部药企密集的资产剥离动作，并非被动收缩，而是在行业重构期主动聚焦核心竞争力的战略选择。创新药企的 “减法”，本质是研发资源的准确投放。如近日，加科思将旗下加科瑞康 80% 股权出售给...
Source Link2025年医药行业，一场集体性的 “战略瘦身” 正在上演。加科思以 2 亿元出售非核心项目股权，和黄医药 44.78 亿元剥离中药资产，复星医药 12.56 亿元转让物业资产，百洋医药清退健康管理业务……业内表示，头部药企密集的资产剥离动作，并非被动收缩，而是在行业重构期主动聚焦核心竞争力的战略选择。创新药企的 “减法”，本质是研发资源的准确投放。如近日，加科思将旗下加科瑞康 80% 股权出售给...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.